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Abstract
Purpose To develop a fully automated procedure for mul-
ticriterial volumetric modulated arc therapy (VMAT) treat-
ment planning (autoVMAT) for stage III/IV non-small cell
lung cancer (NSCLC) patients treated with curative intent.
Materials and methods After configuring the developed au-
toVMAT system for NSCLC, autoVMAT plans were com-
pared with manually generated clinically delivered inten-
sity-modulated radiotherapy (IMRT) plans for 41 patients.
AutoVMAT plans were also compared to manually gen-
erated VMAT plans in the absence of time pressure. For
16 patients with reduced planning target volume (PTV) dose
prescription in the clinical IMRT plan (to avoid violation of
organs at risk tolerances), the potential for dose escalation
with autoVMAT was explored.
Results Two physicians evaluated 35/41 autoVMAT plans
(85%) as clinically acceptable. Compared to the manually
generated IMRT plans, autoVMAT plans showed statisti-
cally significant improved PTV coverage (V95% increased
by 1.1% ± 1.1%), higher dose conformity (R50 reduced by
12.2% ± 12.7%), and reduced mean lung, heart, and esoph-
agus doses (reductions of 0.9 Gy ± 1.0 Gy, 1.5 Gy ± 1.8 Gy,
3.6 Gy ± 2.8 Gy, respectively, all p < 0.001). To render
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the six remaining autoVMAT plans clinically acceptable,
a dosimetrist needed less than 10 min hands-on time for
fine-tuning. AutoVMAT plans were also considered equiv-
alent or better than manually optimized VMAT plans. For
6/16 patients, autoVMAT allowed tumor dose escalation of
5–10 Gy.
Conclusion Clinically deliverable, high-quality autoVMAT
plans can be generated fully automatically for the vast ma-
jority of advanced-stage NSCLC patients. For a subset of
patients, autoVMAT allowed for tumor dose escalation.
Keywords Radiotherapy, intensity-modulated ·
Volumetric-modulated arc therapy · Computer-assisted
radiotherapy planning · Non-small cell lung carcinoma ·
Organs at risk
Vollautomatische VMAT-Behandlungsplanung für
Patienten mit fortgeschrittenem NSCLC
Zusammenfassung
Zielsetzung Entwicklung einer vollautomatisierten, auf
multiplen Kriterien basierenden volumenmodulierten Arc-
Therapie-(VMAT-)Behandlungsplanung (autoVMAT) für
kurativ behandelte Patienten mit nicht-kleinzelligem Bron-
chialkarzinom (NSCLC) im Stadium III/IV.
Material und Methoden Nach Konfiguration unseres au-
toVMAT-Systems für NSCLC wurde für 41 Patienten der
autoVMAT-Plan mit dem manuell erzeugten, klinisch appli-
zierten intensitätsmodulierten Strahlentherapieplan (IMRT)
verglichen. AutoVMAT-Pläne wurden ferner mit manuel-
len und ohne Zeitdruck erstellten VMAT-Plänen verglichen.
Für 16 Patienten mit reduzierter Dosisverordnung des Pla-
nungszielvolumens (PTV) im klinischen IMRT-Plan (zur
Vermeidung einer Verletzung von Toleranzdosen für Risi-
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koorgane) wurde das Potenzial für eine Dosiseskalation mit
autoVMAT untersucht.
Ergebnisse Zwei Ärzte bewerteten 35 von 41 autoVMAT-
Plänen (85 %) als klinisch akzeptabel. Verglichen mit den
manuell erzeugten IMRT-Plänen zeigten autoVMAT-Pläne
eine statistisch signifikant bessere PTV-Abdeckung (V95%
erhöht um 1,1 % ± 1,1 %), eine höhere Dosiskonformität
(R50 verringert um 12,2 % ± 12,7 %) und eine geringere
durchschnittliche Dosis in Lunge, Herz und Oesophagus
(verringert um je 0,9 Gy ± 1,0 Gy, 1,5 Gy ± 1,8 Gy, 3,6 Gy ±
2,8 Gy; alle p < 0,001). Um die restlichen 6 autoVMAT-
Pläne aus klinischer Sicht akzeptabel zu machen, benötig-
te ein Dosimetrist zur Feinabstimmung jeweils weniger als
10 min. AutoVMAT-Pläne wurden verglichen zu manuell
optimierten VMAT-Plänen als gleichwertig oder sogar bes-
ser erachtet. Für 6 von 16 Patienten ermöglichte autoVMAT
eine Dosiseskalation im Tumor um 5–10 Gy.
Schlussfolgerung Für die große Mehrheit von Patienten mit
fortgeschrittenem NSCLC konnte ein klinisch applizierba-
rer, hochqualitativer autoVMAT-Plan vollautomatisch er-
stellt werden. Für eine Subgruppe ermöglichte autoVMAT
eine Dosiseskalation im Tumor.
Schlüsselwörter Intensitätsmodulierte Strahlentherapie ·
Volumenmodulierte Arc Therapie · Vollautomatisierte
Strahlentherapieplanung · Nicht-kleinzelliges
Bronchialkarzinom · Risikoorgane
In recent years, the use of volumetric modulated arc ther-
apy (VMAT) for treatment of locally advanced non-small
cell lung cancer (NSCLC) patients has grown. The main
advantage compared to fixed-field intensity-modulated ra-
diotherapy (IMRT) is its improved delivery efficiency. The
shorter treatment time of VMAT allows for increased pa-
tient throughput, reduced intrafractional motion, and im-
proved patient comfort [1].
IMRT and VMAT treatment planning with commercial
treatment planning systems (TPS) is an iterative trial-and-
error process. The procedure is time consuming and the
quality of the final treatment plan may depend highly on
the experience and skills of the dosimetrist, the complexity
of the case, and the available time. In addition, there is no
guarantee that the final treatment plan reflects the optimal
dose distribution for a specific patient in terms of PTV
coverage, doses in organs at risk (OAR), and the desired
tradeoffs between them.
To increase the consistency and quality of treatment
plans, and to reduce treatment planning time, there is
a growing interest in automated treatment planning [2–16].
Different vendors offer so-called knowledge-based auto-
mated treatment planning solutions. These methods rely
on a database of previously treated plans that are used to
predict achievable dose objectives for a new patient. For
NSCLC patients, several methods for automated treatment
planning have been evaluated. Fogliata et al. used Varian’s
RapidPlan (Varian Medical Systems, Palo Alto, CA, USA),
which applies a database of previously treated plans [12].
Tol et al. used an automated interactive optimization proce-
dure for VMAT plan optimization based on dose–volume
constraints and dose–volume histogram analyses [4]. This
method requires that the user knows the input priorities
that result in acceptable treatment plans for the majority
of patients. Zhang et al. and Quan et al. proposed a com-
pletely automated process based on in-house developed
optimization algorithms [1, 5]. Beam angles were opti-
mized using a library of plans from previously treated
patients. For VMAT and IMRT planning techniques, they
showed that automatically generated plans were gener-
ally preferred by oncologists when compared to manually
generated plans. Recently, Kamran et al. investigated the
benefit of IMRT planning in combination with multicri-
terial optimization [13]. Compared to manually generated
plans without multicriterial optimization, OAR sparing
could be significantly improved without comprising target
coverage. Consequently, the multicriterial optimized plans
were preferred by the physicians.
In the authors’ department, Erasmus-iCycle was devel-
oped, a system for fully automated multicriterial treatment
plan generation. Currently, Erasmus-iCycle is clinically ap-
plied for IMRT and VMAT plan generation for prostate,
head and neck, and cervical cancer patients [3, 6, 14].
The authors have previously demonstrated that automati-
cally generated plans were of noninferior or higher quality
compared to plans generated by an expert dosimetrist in the
absence of time pressure [3].
The goal of this study was to configure, test, and imple-
ment Erasmus-iCycle for automated, multicriterial VMAT
treatment planning (autoVMAT) for stage III/IV NSCLC
patients treated with curative intent. For 41 consecutively
treated patients, autoVMAT plans were compared to manu-
ally generated, clinically delivered IMRT plans using dosi-
metric indices and physicians’ scoring. For a subgroup of
patients, autoVMAT plans were also compared to manually
generated VMAT plans. Sixteen out of 41 patients had a re-
duced PTV dose prescription in the clinical plan to avoid
violation of OAR tolerance doses. For these patients, the
potential for dose escalation with autoVMAT was explored.
Materials and methods
Patients and treatment
Two sets of locally advanced stage III–IV NSCLC patients
treated with curative intent with IMRT at the Erasmus MC
Cancer Institute were included in this study. The first set,
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consisting of 7 patients treated in 2014, was used to config-
ure the system for automated planning. The second set, con-
sisting of 41 consecutive patients treated between January
and August 2015, was used for validation. All clinically
delivered IMRT plans consisted of 5–9 beams and were
generated with the common manual trial-and-error plan-
ning approach, using the Monaco TPS version 5.0 (Elekta
AB, Stockholm, Sweden).
For segmentation of the targets and OARs, the 50% ex-
hale phase of a four-dimensional computed tomography
(4DCT) scan was used. The clinical target volume (CTV)
was defined by expanding the gross tumor volume (GTV)
by a margin of 5 mm. If needed, the CTV was manu-
ally edited based on anatomic borders. Lymph node sta-
tions with affected nodes—as determined on diagnostic CT
or positron-emission tomography (PET) scans, endoscopic
ultrasound, or fine needle aspiration pathology examina-
tion—were also defined as CTV. To define the planning
target volume (PTV), the CTVs of the primary tumor and
lymph nodes were expanded by a margin of 1 cm in the
lateral and ventral–dorsal directions and by a margin of
1–1.2 cm in the cranial–caudal direction, depending on res-
piratory tumor motion amplitude. According to protocol,
the intended PTV dose prescription was 66 Gy. In practice,
prescribed doses varied between 30 and 66 Gy, in order
to avoid violation of clinical constraints. For 25 patients
treated with concurrent chemotherapy, the dose was deliv-
ered in fractions of 2 Gy; 15 patients treated with sequen-
tial chemotherapy received 2.75 Gy per fraction. The other
8 patients, receiving a prescribed dose of 45 Gy or lower,
were treated with 3 Gy per fraction.
Planning goals were to cover at least 95% of the PTV
and 99% of the CTV with 95% of the prescribed dose,
and 99% of the PTV with 90% of the prescribed dose,
while sparing OARs as much as possible. The mean dose
in the total lung volume minus GTV had to be kept below
20 Gy and the V20Gy (volume receiving 20 Gy or more)
below 35%. Maximum allowed doses to the spinal cord and
plexus brachialis were 46.3 Gy and 56.6 Gy (3 Gy/fraction),
49.3 Gy and 60 Gy (2.75 Gy/fraction), and 50 Gy and 66 Gy
(2 Gy/fraction), respectively. The protocol also prescribed
a V5Gy < 60% for lungs minus GTV and V45Gy < 25% for
the esophagus, but these requirements did not determine
whether a plan was deemed acceptable or not. A high level
of dose conformity was desired.
Automated multicriterial treatment planning
The in-house developed Erasmus-iCycle TPS cannot be di-
rectly used for clinical plan generation. Therefore, auto-
mated multicriterial treatment planning was implemented
as a two-step process, combing Erasmus-iCycle and the
clinically used Monaco TPS. The process is described in
detail by Voet et al. [3] and is briefly summarized here.
In the first step, Erasmus-iCycle is used to automatically
generate an equi-angular 23-beam IMRT plan, simulating
VMAT delivery. Further increasing the number of beams
increased calculation times but did not lead to improved
plan quality [3]. Next, using the achieved constraint and
objective values in the Erasmus-iCycle plan, a patient-spe-
cific Monaco template is automatically generated, followed
by automated plan generation in Monaco based on this tem-
plate, to result in a clinically deliverable VMAT plan that
closely mimics the initial Erasmus-iCycle plan. The same
system is used clinically for automated clinical plan gen-
eration for prostate, head and neck, and cervical cancer
patients [3, 6, 14].
Plan generation with Erasmus-iCycle is based on a site-
specific “wishlist”, with hard planning constraints (never to
be violated) and prioritized objectives. The assigned objec-
tive priorities are used to automatically steer the multiobjec-
tive plan generation, ensuring clinically desirable tradeoffs
between all treatment objectives. Generally, adequate PTV
coverage has the highest priority, followed by the most im-
portant OAR objective.
In this study, all Erasmus-iCycle plans were generated by
employing one fixed wishlist, with some minor variations
to handle differences in dose prescription and fractiona-
tion (see above). An initial wishlist was composed based
on previous clinical experience, the planning protocol, and
wishes of treating physicians on how to improve clinically
applied plans. It was used to automatically generate a plan
for the first 7 patients included in this study. These plans
were then evaluated together with physicians, and the wish-
list was modified according to their input. This iterative
procedure continued until no further improvements in plan
quality were achieved for the 7 training patients. The final
wishlist is shown in Table 1.
Comparison of autoVMAT and clinically applied IMRT
plans
For the second group of 41 patients, the manually gen-
erated IMRT plans were compared with autoVMAT plans
using dosimetric indices and by independent scoring by
two physicians. For fair comparison, in this part of the in-
vestigation, the prescribed tumor dose for the autoVMAT
plans was identical to that used in the corresponding clinical
plans.
Comparison of automatically and manually generated
VMAT plans
At the time of this study, the authors did not yet apply
VMAT in clinical routine for advanced-stage NSCLC pa-
tients. Prior to clinical introduction, for 10/41 validation pa-
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Table 1 Erasmus-iCycle wish list for advanced stage NSCLC. The wishlist consists of six hard constraints that are met per definition and
13 objectives that are optimized in order of priority. Once the goal of an objective is achieved or when further optimization is no longer possible,
the optimizer fixes the achieved value of the objective (with a bit of slack) as a constraint and continues with the next objective. The first priority
was proper CTV and PTV coverage, ensured by the use of the LTCP cost function with a sensitivity value of 0.8 [17]. When the spinal cord was
close to the target or overlapped it, the objective was applied to the target volume from which the spinal cord expanded by 5 mm was subtracted.
The purpose was to locate the acceptable underdosage to the PTV near the spinal cord. The third objective aims to reduce the maximum dose at
4 cm from the PTV to 60% of the prescribed dose. The next objective tries to reduce the mean lung dose to 15 Gy. Two more objectives (shell
PTV + 1 cm and shell PTV + 3 cm) with priorities 5 and 6 realize a steep dose falloff outside the PTV. To minimize the esophagus volume
treated to a high dose, an EUD objective were used. Objectives 8 to 13 aimed at further reducing the doses to the OARs. In the final phase of the
optimization, all objectives are consecutively minimized to their fullest extent
Priority Volume Dose metrics Limit/goal Parameter
Constraint Patient Max 107% of prescribed dose –
Constraint CTV Max 107% of prescribed dose –
Constraint PTV—(spinal cord + 5 mm) Max 107% of prescribed dose –
Constraint Spinal cord + 3 mm Max 47 Gy –
Constraint Plexus Max 63 Gy –
Constraint Lungs—GTV Mean 19 Gy –
1 CTV # LTCP 1 α = 0.8
2 PTV # LTCP 0.5 α = 0.8
3 Patient—(PTV + 4 cm) # Max 60% of prescribed dose –
4 Lungs—GTV # Mean 15 Gy –
5 Shell PTV + 1 cm # Max 90% of prescribed dose –
6 Shell PTV + 3 cm # Max 80% of prescribed dose –
7 Esophagus # EUD 44 Gy k = 8
8 Esophagus # Mean 15 Gy –
9 Lungs—GTV # Mean 5 Gy –
10 Heart # Mean 15 Gy –
11 Spinal cord + 3 mm # Max 42 Gy –
12 Unspecified tissue # Max 40 Gy –
13 Plexus # Mean 20 Gy –
LTCP logarithmic tumor control probability, EUD equivalent uniform dose, CTV clinical target volume, GTV gross tumor volume, PTV planning
target volume, NSCLC non-small cell lung cancer, OAR organs at risk. The arrows indicate that objectives are minimized
tients the autoVMAT plans were also compared with VMAT
plans that were manually generated by an expert dosimetrist
without planning time limitations. The dosimetrist had no
prior knowledge of the Erasmus-iCycle plans of these pa-
tients.
Dose escalation
In clinical routine, when it was not possible to achieve the
intended dose prescription of 66 Gy without violating at
least one of the clinical hard constraints, the number of
planned fractions, and consequently the prescribed dose,
was reduced following a standard schedule: 1. reduction of
the prescribed dose to 60 or 60.5 Gy (depending on frac-
tionation schedule), 2. if plan generation was still unfea-
sible, further reduction to 55 Gy, or, if needed, to 45, 39,
or 30 Gy delivered in 3 Gy per fraction. Intermediate dose
levels were not clinically applied due to planning time lim-
itations. For the 16 patients with a prescription dose lower
than 66 Gy, it was attempted to escalate the dose using au-
toVMAT, following the standard schedule steps backwards:
from 45 Gy to 55 Gy, from 55 Gy to 60.5 Gy, from 60 Gy
or 60.5 Gy to 66 Gy. For fair comparison with the clinically
applied procedure, intermediate dose escalations were not
investigated.
Statistics
Plan conformity was quantified using R50, the ratio between
the total volume receiving at least 50% of the prescribed
dose and the volume of the PTV. Dose homogeneity in the
PTV was measured using the homogeneity index (HI), de-
fined as HI = (D2% – D98%)/D50%, where D2%, D98%, and D50%
are the doses covering 2, 98, and 50% of the PTV, respec-
tively. Differences in dosimetric indices were expressed as
mean ±1 standard deviation. Statistical significance of dif-
ferences in dosimetric indices was evaluated with two-tailed
Wilcoxon signed-rank tests, considering p < 0.05 statisti-
cally significant.
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Fig. 1 Differences between clinical intensity-modulated radiotherapy (IMRT) and automated volumetric modulated arc therapy (autoVMAT)
plans for a planning target volume (PTV) V95%, PTV D99%, mean lung dose (MLD), lungs V5Gy, lungs V20Gy; b esophagus mean dose, heart
mean dose, conformity index (R50), and homogeneity index (HI). Positive values are in favor for the autoVMAT plans. V95% is the PTV volume
receiving at least 95% of the prescribed dose, D99% is the minimum dose delivered to 99% of the PTV, V5Gy and V20Gy are the volumes receiving
5 Gy, respectively 20 Gy, or more. For visualization purposes, the differences of PTV D99%, lungs V5Gy and V20Gy, R50, and HI were multiplied by
0.5, 0.2, 0.4, 10, and 100, respectively. Patients for which the autoVMAT plan was rejected are denoted by an *. The pronounced predominance of
positive bars confirms the overall improvement in plan quality for autoVMAT plans with respect to the corresponding clinical IMRT plans
Results
AutoVMAT and clinically applied IMRT plans
Two physicians judged 35/41 of the autoVMAT plans (85%)
as clinically acceptable. These plans were considered equiv-
alent or (as in most cases) better than the corresponding
IMRT plans, due to a combination of better PTV coverage
and dose conformity, as well as sparing of the lungs, heart,
and esophagus (Fig. 1 and Table 2). PTV volume receiving
at least 95% of the prescribed dose (V95%) was on aver-
age improved by 1.1% ± 1.1% (p < 0.001) and the near-
minimum dose in the PTV (D99%) by 0.6 Gy ± 1.5 Gy (p =
0.004). The mean lung dose (lungs excluding GTV) was
reduced by 0.9 Gy ± 1.0 Gy (p < 0.001), V20Gy by 1.3% ±
2.1% (p = 0.001), and V5Gy by 3.2% ± 7.6% (p = 0.023).
The esophagus mean dose was on average 3.6 Gy ± 2.8 Gy
(p < 0.001) lower and V45Gy was reduced by 4.6% ± 4.8%
(p < 0.001). The heart mean dose was reduced by 1.5 Gy ±
1.8 Gy (p < 0.001).
The autoVMAT plans were generally more conformal
than the clinical IMRT plans as indicated by a reduction in
R50 by, on average, 12.2% ± 12.7% (p < 0.001). Moreover,
the PTV dose homogeneity improved by 0.025 ± 0.017 (p <
0.001), i. e., an average reduction of 20%.
Unacceptable plans
For 6 patients, the physicians deemed the autoVMAT plan
clinically unacceptable due to violation of at least one clin-
K
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Table 2 Mean values and uncertainties, reported as one standard deviation (1 SD), for the evaluated dose metrics of the clinical IMRT plans and
the autoVMAT plans for the 35 study patients with acceptable autoVMAT plans. For all metrics, statically significant differences were observed in
a two-tailed Wilcoxon signed-rank test
Clinical IMRT autoVMAT p-value Wilcoxon
testDose metrics Mean SD Mean SD
PTV V95% (%) 97.0 1.4 98.2 1.1 <0.001
PTV D99% (Gy) 55.2 8.9 55.8 9.1 0.004
Conformity index R50 (–) 4.67 0.85 4.13 0.56 <0.001
Homogeneity index (–) 0.127 0.035 0.101 0.035 <0.001
Mean lung dose (Gy) 17.3 2.6 16.5 2.3 <0.001
Lungs V5Gy (%) 56.0 10.6 52.8 9.7 0.023
Lungs V20Gy (%) 29.4 4.8 28.1 4.4 0.001
Mean heart dose (Gy) 12.3 6.6 10.8 5.9 <0.001
Mean esophagus dose (Gy) 24.4 6.9 20.8 6.5 <0.001
Esophagus V45Gy (%) 27.0 13.2 22.4 11.9 <0.001
IMRT intensity-modulated radiotherapy, autoVMAT automated volumetric modulated arc therapy, PTV planning target volume. V95% is the PTV
volume receiving at least 95% of the prescribed dose, D99% is the minimum dose delivered to 99% of the PTV. V5Gy, V20Gy and V45Gy are the
volumes receiving respecively 5 Gy, 20 Gy and 45 Gy, or more
ical constraint. In 2 patients PTV coverage was not ade-
quate (V95 < 95%, V90 < 99%); for 4 patients the MLD
and/or lungs V20Gy exceeded clinical constraints. It took
a dosimetrist less than 10 min hands-on time to manually
fine-tune these plans in Monaco, rendering them accept-
able. In contrast, 3–4 h were required to generate a VMAT
plan from scratch.
AutoVMAT and manually generated VMAT plans
A radiation oncologist evaluated all autoVMAT plans as
equivalent or better in quality compared to the manually
generated VMAT plans. Average differences were not sta-
tistically significant, except for lungs V5Gy (reduction by
6.3% ± 3.3%; p = 0.008), esophagus mean dose (reduction
by 2.2 ± 1.8 Gy; p = 0.012), and esophagus V45Gy (reduc-
tion by 3.2% ± 2.3%; p = 0.012), all in favor of autoVMAT
plans. The manually generated plans were slightly more
conformal, as expressed by a difference in R50 of 8% ± 10%
(p = 0.038). The differences in dose metrics are shown in
Fig. 2.
Dose escalation
For 6/16 patients with a prescription dose less than 66 Gy,
a clinically acceptable autoVMAT plan with a higher pre-
scribed tumor dose could be generated. In 2 patients dose
escalation from 45 to 55 Gy was possible, in 2 further pa-
tients from 60 to 66 Gy. For 1 patient the dose could be
escalated from 55 to 60.5 Gy and for another from 60.5 to
66 Gy. In all cases, the physicians preferred the plan with
the higher tumor dose.
Discussion
This study developed a method for fully automated VMAT
treatment planning for NSCLC patients based on Erasmus-
iCycle. A single wishlist was used for all patients treated
with the same protocol. The Erasmus-iCycle dose distribu-
tions were converted automatically into clinically deliver-
able Monaco VMAT plans. It was shown that autoVMAT
plans were of equivalent or, as in most cases, higher qual-
ity than the clinically applied IMRT plans. This may be at-
tributed partly to the delivery technique (VMAT vs. IMRT),
as was also observed previously [1], and partly to the diffi-
culty of manually selecting the optimal IMRT beam config-
uration for individual patients. AutoVMAT plans were also
of a higher or equivalent quality when compared to VMAT
plans generated by an expert dosimetrist in the absence of
time constraints. Only in 6/41 cases were autoVMAT plans
not clinically acceptable, and a dosimetrist needed only
10 min to make these plans fulfil the constraints. The au-
tomated procedure led to a decrease in hands-on treatment
planning time of 3–4 h per patient compared to conven-
tional VMAT planning. Based on these results, autoVMAT
has been clinically applied for all advanced-stage NSCLC
patients treated with curative intent at the authors’ hospital
since March 2016.
In previous studies for prostate, head and neck, and cer-
vical cancer [3, 6, 14], it was not observed that some of
the autoVMAT plans were unacceptable and of a lesser
quality than manually generated IMRT plans with the same
prescribed dose. The authors believe that this may be at-
tributed to the simple pencil beam dose calculation algo-
rithm in Erasmus-iCycle [17]. For NSCLC patients, this
may result in high-quality Erasmus-iCycle plans that can-
not be accurately mimicked with the advanced Monte Carlo
K
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Fig. 2 Differences between manually generated volumetric modu-
lated arc therapy (VMAT) plans and automated VMAT (autoVMAT)
plans for a planning target volume (PTV) V95%, PTV D99%, mean lung
dose (MLD), lungs V5Gy, and lungs V20Gy, and b esophagus mean dose,
heart mean dose, conformity index (R50) and homogeneity index (HI).
V95% is the PTV volume receiving at least 95% of the prescribed dose,
D99% is the minimum dose delivered to 99% of the PTV, V5Gy and
V20Gy are the volumes receiving 5 Gy, respectively 20 Gy, or more.
Positive values are in favor of the autoVMAT plans. For visualization
purposes, the differences of the lungs V5Gy and V20Gy and HI were
multiplied by 0.2, 0.4, and 100, respectively. Positive values for PTV
coverage are often coupled with negative values for MLD and vice
versa
dose engine in Monaco. Therefore, in an ongoing project,
the Monte Carlo engine used in Monaco is coupled to Eras-
mus-iCycle. It is expected that, in the near future, this will
avoid generation of unacceptable plans for NSCLC patients
as well.
For a considerable proportion of advanced-stage NSCLC
patients, a prescribed dose of 66 Gy is not achievable. In
these cases, the prescribed dose has to be lowered to yield
acceptable OAR doses. This can be a tedious process and
the clinical protocol was therefore to lower the prescribed
dose in fixed steps of multiple fractions. With autoVMAT
it is now feasible to apply individualized dose reductions,
avoiding PTV doses lower than strictly needed.
Erasmus-iCycle for autoVMAT planning has a couple
of advantages compared to other approaches for automated
(VMAT) planning. First, it does not fully rely on a database
of prior patients, as published knowledge-based approaches
do [1, 4, 5, 12]. A small set of training patients (10) is
only used as starting point for establishing a site-specific
wishlist. When generating this wishlist, the explicit aim is
to achieve a higher plan quality than in the clinical plans
of the training patients. With this procedure, automatically
generated plans for previously treated patients have, on av-
erage, a higher or at least non-inferior plan quality than the
clinical plans [3], as also shown in this work. The need for
a small set of training patients has an additional advantage
in case of changes in clinical protocol, which would other-
wise require a new large database of high-quality plans.
Conclusion
Fully automated VMAT treatment planning was imple-
mented for advanced-stage NSCLC. For the vast majority
of patients, autoVMAT plans were equivalent or better than
manually generated plans. Moreover, for a subset of pa-
tients, autoVMAT allowed for tumor dose escalation within
clinical constraints. Consequently, autoVMAT has been
applied for NSCLC in routine clinical use at the authors’
hospital since March 2016.
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